AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).

Employees

55,000

Sector

Pharmaceuticals

Calendar

10-22 - Q3 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-02-13	231.50 $	+1.76%	8,252,480
26-02-12	227.50 $	+2.99%	8,712,013
26-02-11	220.89 $	-0.70%	8,072,636
26-02-10	222.44 $	-0.37%	6,044,475
26-02-09	223.26 $	-0.08%	6,767,650

Delayed Quote Nyse

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

231.50USD

Average target price

245.33USD

Spread / Average Target

+5.98%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 16:00:03 2026-02-13 EST			5-day change	1st Jan Change
231.50 ^USD	+1.76%		+3.61%	+1.32%

02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-12	AbbVie sues US health agency over Botox price controls	RE

Capitalization	409B 345B 314B 300B 557B 37,058B 579B 3,657B 1,452B 17,896B 1,534B 1,503B 62,546B	P/E ratio 2025	96.8x	P/E ratio 2026 *	23.6x
Enterprise value	466B 392B 358B 342B 634B 42,169B 659B 4,162B 1,652B 20,364B 1,746B 1,710B 71,173B	EV / Sales 2025	6.6x	EV / Sales 2026 *	6.82x
Free-Float	96.39%	Yield 2025 *	2.82%	Yield 2026 *	3%

02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-12	AbbVie sues US health agency over Botox price controls	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026	CI
02-11	AbbVie sues US health agency over Botox	RE
02-11	AbbVie sues U.S. Department of Health and Human Services over selection of Botox for IRA Medicare drug negotiations	RE
02-09	BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating	MT
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT
02-05	Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating	MT
02-05	Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating	MT
02-04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
02-04	Nasdaq, S&P 500 Fall as Tech Sell-Off Continues	MT
02-04	Evercore ISI Adjusts AbbVie Price Target to $228 From $232, Maintains Outperform Rating	MT

02-09	BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating	MT
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT
02-05	Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating	MT
02-05	UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating	MT
02-05	Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating	MT

AbbVie Inc. Stock

Equities

ABBV

US00287Y1091

Pharmaceuticals

Valuation: AbbVie Inc.

Chart: AbbVie Inc.

Latest news: AbbVie Inc.

Last Transcript: AbbVie Inc.

Analysts' recommendations: AbbVie Inc.

Press Releases: AbbVie Inc.

News in other languages: AbbVie Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbbVie Inc.

ETFs: AbbVie Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-04	AbbVie : Pipeline Update (ec207e)	PU
02-04	AbbVie : ABBV 4Q25 Press Release Final	PU
02-04	AbbVie: Q4 Earnings Snapshot	AQ
02-04	AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results	PR
02-03	Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program	PR

02-12	Bourse : EssilorLuxottica, Hermès et Unibail publient, Sanofi perd sa tête
02-12	Des résultats qui ne pardonnent pas
02-05	Wall Street clôture sans direction claire
02-04	MÄRKTE USA/Wall Street von KI-Modellen erneut belastet
02-04	MÄRKTE USA/Wall Street von KI-Modellen belastet

1 day	+1.76%
1 week	+3.61%
Current month	+3.81%
1 month	+4.87%
3 months	-0.34%
6 months	+14.91%
Current year	+1.32%

1 week	218.05	234.74
1 month	204.27	234.74
Current year	204.27	237.04
1 year	164.39	244.81
3 years	130.96	244.81
5 years	102.05	244.81
10 years	52.73	244.81

Manager	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	55	2024-06-30
Scott Reents DFI	Director of Finance/CFO	59	2022-06-22
Roopal Thakkar CTO	Chief Tech/Sci/R&D Officer	-	2002-12-31

Director	Title	Age	Since
Roxanne Austin BRD	Director/Board Member	65	2012-12-31
William Burnside BRD	Director/Board Member	74	2012-12-31
Edward Rapp BRD	Director/Board Member	68	2012-12-31

Name		Varia. Jan 1.	Weight	AuM
FIRST TRUST MORNINGSTAR DIVIDEND LEADERS ETF (CAD-HEDGED) - CAD		0.00%	7.12%	6 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY		-0.48%	6.85%	26 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ABBVIE INC.	+1.76%	+3.61%	+19.67%	+50.59%	409B
ELI LILLY AND COMPANY	+0.33%	-1.72%	+19.29%	+196.80%	929B
JOHNSON & JOHNSON	-0.45%	+1.44%	+54.82%	+49.59%	587B
ROCHE HOLDING AG	+0.08%	+1.01%	+20.89%	+28.94%	374B
ASTRAZENECA PLC	+1.42%	+7.19%	+26.36%	+32.36%	320B
NOVARTIS AG	+1.08%	+4.32%	+27.98%	+55.61%	311B
MERCK & CO., INC.	+1.82%	-0.43%	+43.82%	+10.83%	301B
NOVO NORDISK A/S	+1.32%	+5.11%	-45.12%	-37.51%	219B
AMGEN INC.	+1.52%	-3.94%	+24.32%	+51.52%	199B
GILEAD SCIENCES, INC.	+2.09%	+1.63%	+46.26%	+77.14%	192B
Average	+1.10%	+1.96%	+23.83%	+51.59%	384.09B
Weighted average by Cap.	+0.81%	+1.58%	+26.06%	+75.81%

	2025	2026 *
Net sales	60.96B 51.36B 46.85B 44.73B 83.02B 5,521B 86.26B 545B 216B 2,666B 229B 224B 9,318B	67.11B 56.55B 51.58B 49.24B 91.4B 6,078B 94.97B 600B 238B 2,935B 252B 246B 10,259B
Net income	7.42B 6.26B 5.71B 5.45B 10.11B 672B 10.51B 66.37B 26.35B 325B 27.84B 27.27B 1,135B	17.16B 14.46B 13.19B 12.59B 23.37B 1,554B 24.29B 153B 60.9B 751B 64.36B 63.04B 2,624B
Net Debt	56.43B 47.55B 43.37B 41.4B 76.86B 5,111B 79.85B 504B 200B 2,468B 212B 207B 8,626B	48.21B 40.62B 37.05B 35.37B 65.66B 4,367B 68.23B 431B 171B 2,109B 181B 177B 7,370B